Vantage logo

Amarin enters the home stretch

After an overwhelmingly positive adcom, the outstanding question around Vascepa is just how big the product might become.

Vantage logo

Roxadustat moves on to the regulators

A cardiac safety analysis should calm some concerns over Astrazeneca and Fibrogen’s new anaemia pill, though regulators’ views on the hugely complex programme remain…

Vantage logo
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.